Cancer Vaccine Moves Closer to FDA Approval

With the news of Dendreon Corporation's announcement yesterday at the annual meeting in Chicago of the American Urological Association that its investigational active cellular immunotherapy for advanced prostate cancer, PROVENGE (sipuleucel-T), extended patient survival by 4.1 months and increased 3-year survival by 38 percent compared to placebo, the field of tumor immunology has taken a significant leap forward as this, the first active cellular immunotherapy shown in a phase III clinical trial to benefit patients, moves closer to FDA approval.

According to experts in the field of tumor immunology, this is an important milestone achievement--within the scope of the history of tumor immunology and the decades of effort to bring effective cancer immunotherapies to patients, the impact of PROVENGE specifically on prostate cancer therapy today, and the broader import this has and as it bears on cancer vaccine discovery and development efforts currently underway within academic and industry domains.

The Cancer Research Institute, a non-profit organization the supports and coordinates laboratory and clinical efforts leading to the immunological treatment, control, and prevention of cancer, is a global leader in cancer vaccine development. The CRI/LICR Cancer Vaccine Collaborative--a centralized network of more than 20 top academic clinical trial sites with immunological monitoring capability engaged in single-variable, first-in-man cancer vaccine studies, formed in partnership with the Ludwig Institute for Cancer Research Ltd--and its Cancer Vaccine Consortium--a membership association of more than 60 pharmaceutical and biotechnology companies and academic institutions who share a common goal of making cancer vaccines part of the standard-of-care for cancer patients--together comprise the world's leading experts in cancer vaccine discovery and development from both academia and industry.

Cancer Research Institute can provide expert commentary on the importance of the PROVENGE study results and what they mean for the field of tumor immunology, for cancer patients, and for the future of cancer therapy, as well as key challenges still facing the field, including vaccine reagent access, intellectual property concerns, regulatory issues, protocol design, RECIST criteria, and strategies that work to bridge the divide between academic and industry interests.

Suggested Expert:

Lloyd J. Old, M.D.

Lloyd J. Old, M.D., is chairman of the Board of Directors of the Ludwig Institute for Cancer Research Ltd. Previously, he was director and chief executive officer of the Ludwig Institute. He has been associated with the Memorial Sloan-Kettering Cancer Center since 1958, first as a research fellow. He was appointed associate director of research in 1973 of Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and Allied Diseases and was named the William E. Snee Chair of Cancer Immunology in 1983.

Lloyd J. Old, M.D., is one of the pioneers in tumor immunology, having made some of the most important contributions to that field from both the lab bench and the board room table. He is one of the most highly cited researchers in the field, and is an international award-winning scientific luminary who has helped to forge alliances among academic and industry interests in order to accelerate the scientifically prudent advancement of cancer vaccines.

For a more detailed biography of Dr. Old, visit:
http://www.cancerresearch.org/board/Lloyd-Old.html

For a description of Dr. Old's key scientific contributions, visit:
http://www.cancerresearch.org/Programs.aspx?id=2290

Views: 44

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

"Destroying the New World Order"

TOP CONTENT THIS WEEK

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

Latest Activity

cheeki kea commented on Doc Vega's blog post Government Issued Wearables? What’s Wrong With this Picture?
"I wonder what wearables must have been like before the last reset. "
11 hours ago
Burbia commented on Burbia's video
18 hours ago
Doc Vega posted blog posts
19 hours ago
Doc Vega commented on tjdavis's blog post National Blueprint For Biodefense
"Another scare tactic to push people into anew regime of vaccinations! Either that, or this is a…"
20 hours ago
Sandy posted a video

Dr. Mike Yeadon Speaks Out Against Digital ID, CBDCs, and Agenda 2030

Dr. Mike Yeadon, ex-Pfizer VP, urges public rejection of digital ID, CBDCs, and Agenda 2030, warning of future restrictions on freedom and privacy.
yesterday
Doc Vega posted blog posts
yesterday
Burbia posted a video

"EVERYONE'S BEEN SHOT UP HERE": Arsonists Set Wildfire In Idaho, Open Fire On Firefighters, Police

- Shocking news just broke that multiple firefighters and officers were shot in an ambush at the Canfield Mountain Natural Area in Coeur d'Alene, Idaho.Acco...
Monday
Doc Vega posted a blog post

The Draconian Show

Sometimes I talk to my invisible friend, IkeHe comes from another dimension when magnetic fields…See More
Friday
tjdavis posted a blog post
Jun 26
Doc Vega posted a blog post
Jun 25
Doc Vega posted blog posts
Jun 24
Doc Vega posted blog posts
Jun 23
Doc Vega favorited tjdavis's photo
Jun 22
Doc Vega commented on tjdavis's photo
Thumbnail

Game Night

"Ha! Good one!"
Jun 22
Doc Vega commented on FREEDOMROX's blog post MRNA VACCINES: Question
"Listen man I know where you're at but back in October of 2023 thru December of 2023 for months…"
Jun 22
tjdavis posted a video

Architecton | Official Trailer HD | A24

SUBSCRIBE: http://bit.ly/A24subscribeWritten and directed by Victor Kossakovsky and starring Michele De Lucchi. ARCHITECTON – Coming Soon RELEASE DATE: Comin...
Jun 22
tjdavis posted photos
Jun 22
tjdavis posted a blog post
Jun 21
Burbia posted a video

Europe Will Not Survive

The hubris.All things Archaix at www.archaix.com
Jun 21
FREEDOMROX posted a video
Jun 21

© 2025   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted